Article Details
Retrieved on: 2024-09-25 20:33:56
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Georgiamune Inc.'s progress in biotech, specifically their phase 1 trial for an autoimmune disease treatment via GIM-407, emphasizing regulatory T cell activation and innovation in immunotherapy for conditions like Sjögren syndrome.
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here